Filing Overview
Registrant: Foresight Acquisition Corp.; the filing concerns its proposed business combination with P3 Health Group Holdings, LLC, the predecessor entity of P3 Health Partners. Report date: May 25, 2021. The filing is a Form 8-K under Items 7.01, 8.01 and 9.01 and includes a joint press release and investor presentation as exhibits.
Transaction and Business Context
Foresight and P3 entered into a merger agreement with FAC Merger Sub LLC. Subject to satisfaction or waiver of closing conditions, P3 will merge with and into the merger subsidiary, which will survive.
- The post-closing structure is expected to be an “Up-C” structure.
- P3’s operating subsidiaries will be held directly or indirectly by the surviving entity.
- Foresight is expected to own approximately 30% of the surviving entity and become its sole manager.
- The proposed business combination requires stockholder approval and other customary closing conditions, including potentially required regulatory approvals.
Financial Metrics and Liquidity
The provided filing text does not include clear historical or projected values for revenue, profit or loss, cash flow, margins, debt, liquidity, valuation, purchase consideration, or other operating metrics. The attached investor presentation and press release may contain additional financial information, but their substantive contents are not included in the provided text.
Changes Versus Prior Period
This is a transaction announcement rather than a periodic financial report. The filing does not provide comparable-period financial statements or quantify changes in operating or financial performance.
Outlook, Risks and Contingencies
- Completion is not assured and depends on stockholder approval, regulatory approvals where required, and other closing conditions.
- Public stockholder redemption levels may affect the transaction and the post-closing capitalization.
- The parties caution that projected financial information and anticipated transaction benefits are uncertain and may not be realized.
- Identified risks include economic and market conditions, legal and regulatory developments, competition, management of growth, product and platform development, financing and future equity issuance, litigation, investigations and regulatory proceedings.
- Forward-looking statements are based on management assumptions and are not guarantees of future performance.
- Any private placement securities would be unregistered and subject to transfer restrictions until resale registration or an applicable exemption is available.
Key Facts to Verify
- Review the definitive proxy statement for the complete merger terms, valuation, ownership percentages, dilution and required approvals.
- Verify the closing conditions, regulatory requirements and expected transaction timetable.
- Review P3’s historical and projected revenue, profitability, cash flow, debt and liquidity information in the proxy statement or related filings.
- Assess the potential impact of public stockholder redemptions and any private placement financing on post-closing capitalization.
- Confirm whether the proposed transaction closes and whether the anticipated Up-C structure and approximately 30% Foresight ownership are implemented as described.